Activity of Pramlintide, Rat and Human Amylin but not Aβ1-42 at Human Amylin Receptors

Endocrinology

Volumn 155, Issue 1, 2014, Pages 21-26

  Gingell, Joseph J ^a,b   Burns, Erica R ^a   Hay, Debbie L ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLIN RECEPTOR; AMYLIN RECEPTOR 1; AMYLIN RECEPTOR 2; AMYLIN RECEPTOR 3; AMYLOID BETA PROTEIN[1-42]; CALCITONIN RECEPTOR; CYCLIC AMP; PRAMLINTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HORMONE ACTION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; KIDNEY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84891375601     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1658     Document Type: Article

References (27)

1. Lutz TA. Effects of amylin on eating and adiposity. In: Joost, H-G, ed. Handbook of Experimental Pharmacology. Berlin, Germany: Springer-Verlag; 2012;231-250.
2. Hanabusa T, Kubo K, Oki C, et al. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1992;15:89-96.
3. Mäkimattila S, FinemanMS,Yki-Järvinen H. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes. J Clin Endocrinol Metab. 2000;85:2822-2827.
4. Roth JD,MackCM,Soares CJ, Ghosh SS, Parkes DG. Amylin-based pharmacotherapy - past, present future. Immunol Endocr Metab Agents Med Chem. 2008;8:317-324.
5. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91: 795-826.
6. Rushing PA, Hagan MM, Seeley RJ, et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology. 2001;142:5035.
7. Rushing PA, Seeley RJ, Air EL, Lutz TA, Woods SC. Acute 3rdventricular amylin infusion potently reduces food intake but does not produce aversive consequences. Peptides. 2002;23:985-988.
8. Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. Ann Pharmacother. 2010;44:538-545.
9. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA. 2008;105:7257-7262.
10. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54:233-246.
11. Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM. Pharmacological discrimination of calcitonin receptor: Receptor activity-modifying protein complexes. Mol Pharmacol. 2005; 67:1655-1665.
12. Morfis M, Tilakaratne N, Furness SG, et al. Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology. 2008;149:5423-5431.
13. Gingell JJ, Qi T, Bailey RJ, Hay DL. A key role for tryptophan 84 in receptor activity-modifying protein 1 in the amylin 1 receptor. Peptides. 2010;31:1400-1404.
14. Qi T, Dong M, Watkins HA, Wootten D, Miller LJ, Hay DL. Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant -(1-47)hCT((a)) function. Br J Pharmacol. 2013;168:644-657.
15. Bailey RJ, Walker CS, Ferner AH, et al. Pharmacological characterization of rat amylin receptors: Implications for the identification of amylin receptor subtypes. Br J Pharmacol. 2012;166:151-167.
16. Tilakaratne N, Christopoulos G,ZumpeET, FoordSM,SextonPM. Amylin receptor phenotypes derived from human calcitonin receptor/ RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther. 2000;294:61-72.
17. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience. 1994;62:553-567.
18. Christopoulos G, Paxinos G, Huang XF, Beaumont K, Toga AW, Sexton PM. Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol. 1995;73:1037-1041.
19. Becskei C, Riediger T, Zund D, Wookey P, Lutz TA. Immunohistochemical mapping of calcitonin receptors in the adult rat brain. Brain Res. 2004;1030:221-233.
20. Barth SW, Riediger T, Lutz TA, Rechkemmer G. Peripheral amylin activates circumventricular organs expressing calcitonin receptor a/b subtypes and receptor-Activity modifying proteins in the rat. Brain Res. 2004;997:97-102.
21. Ueda T, Ugawa S, Saishin Y, Shimada S. Expression of receptoractivity modifying protein (RAMP)mRNAsin the mouse brain. Mol Brain Res. 2001;93:36-45.
22. Young AA, Vine W, Gedulin BR, et al. Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin. Drug Dev Res. 1996;37:231-248.
23. Fu W, Ruangkittisakul A, MacTavish D, Shi JY, Ballanyi K, Jhamandas JH. Amyloid β (A β) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem. 2012;287:18820-18830.
24. Kimura R, MacTavish D, Yang J, Westaway D, Jhamandas JH. β-Amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. J Neurosci. 2012; 32:17401-17406.
25. Harris PWR, Kowalczyk R, Hay DL, Brimble MA. A single pseudoproline and microwave solid phase peptide synthesis facilitates an efficient synthesis of human amylin 1-37. Int J Pept Res Ther. 2012; 1-9.
26. Bailey RJ, Hay DL. Pharmacology of the human CGRP1 receptor in Cos 7 cells. Peptides. 2006;27:1367-1375.
27. Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426:900-904.